AlphAIAlphAI — Financial news for AI agents
investing.comOCT 262 min read$CMPS

B.Riley reiterates Buy on Compass Pathways stock, $22 target

B.Riley reiterated a Buy rating and $22 target on Compass Pathways (CMPS) after the VA selected sites for psychedelic deployment. CMPS is up 78% over the past year and 62% YTD, trading at $11.15. The company's COMP360 therapy could begin dosing soon, with FDA approval possible within 3-6 months. B.Riley estimates significant revenue potential from VA patients. Analysts highlight positive trial data and strong financial position.

Original reporting
investing.com
Published Oct 26, 2026, 6:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 6:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CMPS
Bullish
high confidence
Mentioned
$CMPS
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CMPSBullishMed
01

Why it matters

The analyst upgrade and VA contract potential provide a fresh catalyst that could attract new capital, supporting a price rally toward the new target.

02

Market read

The news directly affects CMPS stock and may influence sentiment across the psychedelic biotech sector.

03

What to watch

Potential competition from other psychedelic developers and the need for further FDA clearance could temper upside.

Relevance 7/10Novelty 6/10Timing: today

Background

Compass Pathways (CMPS) is a U.S.-listed biotech developing psilocybin‑based treatments for treatment‑resistant depression. Recent analyst coverage highlighted a new buy rating and a $22 price target following VA site selection and positive Phase 3 data.

Company-level read

Ticker impact

$CMPSBullishHigh confidence
Context

B.Riley reiterated a Buy rating and raised the price target to $22 after the VA selected sites for psychedelic deployment and new Phase 3 trial data were reported.

Expected impact

likely upward as investors price in higher target and potential VA contracts

Evidence & confidence

The combination of a fresh buy rating, higher target, and VA site selection provides a concrete catalyst for near‑term demand.

Market effects

Sector

Positive outlook for psychedelic therapeutics may lift peers in the mental‑health biotech space.

Regional

U.S. biotech sector could see modest gains as investors reassess valuation multiples.

Global

Limited to U.S. and global biotech investors focused on novel therapies.

Counterpoint

What could challenge this read

The VA site selection may be preliminary and regulatory approval remains uncertain, keeping downside risk.

Key entities

  • Analyst
    B. Riley

    Equity research firm that issued the reiterated Buy rating and $22 target.

  • Government Agency
    U.S. Department of Veterans Affairs (VA)

    Selected 10 sites for future psychedelic deployment, creating a potential revenue pipeline.

Read at source← All news

Related articles

NOV 3
$CMPSMedAI 8/10

Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights

COMPASS Pathways plc (CMPS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights • Final NDA submission nearing completion and will be filed in the next two weeks • Launch readiness on track for expected launch in H12027, subject to FDA approval • Data from two positive Ph

SEC EDGAR 8-K3 min
NOV 3
$CMPSMedAI 8/10

An extra dose extended a depression treatment’s effect to one year in trial data.

Compass Pathways (CMPS) is nearing completion of its NDA submission for COMP360, a treatment for treatment-resistant depression (TRD), with a filing expected in two weeks. Positive Phase 3 trial data shows durability of effect up to one year. The company aims for a H1 2027 launch, subject to FDA approval. COMP360 is seen as a potential blockbuster with a large market opportunity. Compass also has a late-stage PTSD trial ongoing and a strong cash position into 2028.

stocktitan.net2 min
OCT 24
$CMPSHighAI 9/10

Tovecimig Plus Paclitaxel Improves ORR vs Paclitaxel Alone in Biliary Tract Cancer

Tovecimig (CTX-009) plus paclitaxel showed improved objective response rates (18.0% vs 5.3%) over paclitaxel alone in advanced biliary tract cancer, meeting the primary endpoint of the phase 2/3 COMPANION-002 trial. Median PFS was 4.7 months vs 2.6 months, but OS was similar (8.9 vs 9.4 months). The trial involved 168 patients and was presented at the 2026 ESMO Congress. According to Compass Therapeutics, the combination represents a promising new strategy for biliary tract cancer.

onclive.com3 min
OCT 16
$CMPSMedAI 8/10

Can Durable Response to Psilocybin Reshape Treatment-Resistant Depression Care?

Compass Pathways presented real-world analyses showing that treatment-resistant depression (TRD) has significant economic burden during treatment-resistant episodes, with costs declining as patients stabilize. Their psilocybin formulation, COMP360, showed sustained clinical benefit in phase 3 trials, with 25% and 39% of participants achieving meaningful symptom reduction in COMP005 and COMP006, respectively, maintained through week 26.

psychiatrictimes.com3 min